Significance of the endothelin ETA receptor in the haemodynamic and inotropic effects of endothelin-1 in rats

Clinical Science
M E BeyerH M Hoffmeister

Abstract

The main aim of the present study was to investigate the direct inotropic effects of stimulation of the endothelin (ET) receptor ETA under in vivo conditions. It is well known that ETA receptor stimulation causes pronounced vasoconstriction. The ET-1-induced coronary vasoconstriction may lead to myocardial ischaemia and, consequently, to cardiodepressor effects that may mask the direct positive inotropic effect of ETA receptor stimulation. Thus, in the present study, steps were taken to avoid this possibility. In anaesthetized open-chest rats the haemodynamic and inotropic effects of ETA receptor stimulation were studied by monitoring responses evoked by ET-1 (1 nmol/kg of body weight) after ETB receptor blockade with BQ 788 (0.5 micromol/kg of body weight); these responses were compared with saline controls (after ETB receptor blockade). To avoid vasoconstrictor effects induced by ETA receptor stimulation, additional experiments were performed in the presence of the vasodilator adenosine (2.0 mg.kg(-1) of body weight.min(-1)). Myocardial function was also examined during aortic clamping so as to circumvent the effect of changes in afterload. We studied further the effect of ETA receptor stimulation on myocardial energy metabol...Continue Reading

References

Apr 1, 1979·Circulation Research·M A PfefferE Braunwald
Oct 1, 1992·Journal of Cardiovascular Pharmacology·F J RicouK L Peterson
Aug 11, 1992·Mayo Clinic Proceedings·R J RodehefferJ C Burnett
Jul 1, 1990·Journal of Cardiovascular Pharmacology·S NeubauerK Kochsiek
Jul 1, 1991·Journal of the American College of Cardiology·D J StewartP Cernacek
Jan 17, 1991·European Journal of Pharmacology·R DomenechJ P Huidobro-Toro
Dec 30, 1988·Biochemical and Biophysical Research Communications·C Van RenterghemM Lazdunski
Jan 1, 1989·Journal of Cardiovascular Pharmacology·J G ClarkeA Maseri
Jan 1, 1989·Journal of Cardiovascular Pharmacology·A WallnöferC Cauvin
Feb 28, 1989·Biochemical and Biophysical Research Communications·C S MoravecM Bond
Jun 1, 1989·The American Journal of Cardiology·A H ChesterM H Yacoub
Dec 13, 1988·European Journal of Pharmacology·J R HuR E Lang
Jan 1, 1987·Cardiovascular Research·H M HoffmeisterL Seipel
Sep 1, 1983·Circulation Research·L Belardinelli, G Isenberg
Jan 1, 1994·Basic Research in Cardiology·M E BeyerH M Hoffmeister
Mar 30, 1994·Biochemical and Biophysical Research Communications·T FukurodaM Nishikibe
May 24, 1994·Proceedings of the National Academy of Sciences of the United States of America·K IshikawaT Nagase
Mar 15, 1993·Biochemical and Biophysical Research Communications·S S ShettyR W Lappe
Apr 6, 2000·The Annals of Thoracic Surgery·A T GoldbergF G Spinale

❮ Previous
Next ❯

Citations

Aug 26, 2006·Journal of Cardiovascular Medicine·Claudia PennaGianni Losano

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiomyopathy

Cardiomyopathy is a disease of the heart muscle, that can lead to muscular or electrical dysfunction of the heart. It is often an irreversible disease that is associated with a poor prognosis. There are different causes and classifications of cardiomyopathies. Here are the latest discoveries pertaining to this disease.

Antihypertensive Agents: Mechanisms of Action

Antihypertensive drugs are used to treat hypertension (high blood pressure) which aims to prevent the complications of high blood pressure, such as stroke and myocardial infarction. Discover the latest research on antihypertensive drugs and their mechanism of action here.